Previous 10 | Next 10 |
Eli Lilly & Co. (LLY), AbbVie Inc. (ABBV), Zoetis Inc. (ZTS) and Neurocrine Biosciences Inc. (NBIX) are stocks that could move significantly higher in the second half of this year. Pharmaceutical stocks have been soaring in the past couple of months. Many are nearing their 52-wee...
Neurocrine Biosciences ( NBIX ) management has been clear that they want to reinvest the company’s growing financial resources into expanding the clinical pipeline and, eventually, the business. This has been more than just talk, with multiple deals ( Idorsia , Xenon ( XENE ), Voya...
Neurocrine Biosciences (NASDAQ: NBIX ) inks an agreement with Takeda Pharmaceutical Company Limited (NYSE: TAK ) for exclusive rights to seven Takeda programs in psychiatry, including three clinical-stage assets for the potential treatment of schizophrenia (TAK-831), treatment-resistant de...
Strategic partnership agreement provides Neurocrine Biosciences exclusive worldwide rights to early-to-mid-stage psychiatry pipeline compounds within Takeda’s Neuroscience portfolio Collaboration includes three clinical-stage assets with the most advanced molecule in Phase...
SAN DIEGO , June 15, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Securities 2020 Napa Biopharma Conference at 2:00 p.m. PT ( 5:00 p.m. ET ) on Monday, June 22, 2020 . Kevin Gorman , Chief Executive Officer, will present at the c...
While Neurocrine Biosciences ( NBIX ) had previously announced positive top-line Phase II data for its congenital adrenal hyperplasia (or CAH) drug crinecerfont, a fuller presentation of the trial results through the ENDO 2020 online meeting continues to support the notion that this is a wor...
In this episode of Industry Focus: Wildcard , Dylan Lewis chats with Motley Fool contributor Brian Feroldi about valuable lessons from a company working on a COVID-19 vaccine, the various clinical trial phases a drug has to undergo, how biotech companies generate revenues, how they are valued...
SAN DIEGO , June 8, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced positive data from its completed open-label, multiple-dose, dose-finding, Phase II clinical study of crinecerfont (NBI-74788), demonstrating meaningful reductions in all three key...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
SAN DIEGO , June 4, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 41 st Annual Global Healthcare Conference Webcast at 9:40 a.m. ET on Thursday , June 11, 2020. Kevin Gorman , Chief Executive Officer, Eiry Roberts, Chief Medical...
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
A look at the top 10 most actives in the United States Redhill Biopharma Ltd. (RDHL) rose 41.5% to $0.5434 on volume of 82,457,301 shares FSD Pharma Inc. (HUGE) rose 9.8% to $0.1109 on volume of 60,485,300 shares NVIDIA Corporation (NVDA) rose 2.3% to $119.75 on volume of 54,756,180 shares ...
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance PR Newswire INGREZZA ® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA ...
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing PR Newswire SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX...